Point72 Asset Management L.P. Has $2.61 Million Holdings in Enhabit, Inc. (NYSE:EHAB)

Point72 Asset Management L.P. cut its stake in shares of Enhabit, Inc. (NYSE:EHAB - Free Report) by 28.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 330,400 shares of the company's stock after selling 130,666 shares during the period. Point72 Asset Management L.P. owned 0.66% of Enhabit worth $2,610,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC increased its stake in Enhabit by 138.4% during the 3rd quarter. FMR LLC now owns 3,388 shares of the company's stock worth $27,000 after buying an additional 1,967 shares during the period. Gladius Capital Management LP acquired a new stake in Enhabit during the 2nd quarter valued at approximately $31,000. Quarry LP increased its holdings in Enhabit by 242.2% during the 2nd quarter. Quarry LP now owns 3,703 shares of the company's stock worth $33,000 after purchasing an additional 2,621 shares during the last quarter. Stoneridge Investment Partners LLC acquired a new position in shares of Enhabit in the 3rd quarter valued at approximately $81,000. Finally, Canada Pension Plan Investment Board acquired a new stake in Enhabit in the second quarter valued at $93,000.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on EHAB shares. Leerink Partners reaffirmed a "market perform" rating and set a $8.00 price target (down previously from $8.50) on shares of Enhabit in a research report on Tuesday, November 19th. Jefferies Financial Group upgraded Enhabit from a "hold" rating to a "buy" rating and boosted their price target for the company from $8.25 to $9.50 in a report on Monday. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat, Enhabit currently has a consensus rating of "Hold" and a consensus price target of $9.40.

Enhabit Stock Performance

Enhabit stock traded down $0.02 during midday trading on Tuesday, reaching $8.73. 197,274 shares of the stock traded hands, compared to its average volume of 574,896. The firm has a fifty day moving average price of $7.48 and a two-hundred day moving average price of $8.31. Enhabit, Inc. has a fifty-two week low of $6.85 and a fifty-two week high of $11.74. The firm has a market cap of $438.98 million, a price-to-earnings ratio of -3.77 and a beta of 1.89. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85.

Enhabit (NYSE:EHAB - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.01). The business had revenue of $253.60 million for the quarter, compared to analyst estimates of $261.69 million. Enhabit had a positive return on equity of 1.67% and a negative net margin of 11.24%. During the same quarter last year, the firm posted $0.03 EPS. On average, equities research analysts forecast that Enhabit, Inc. will post 0.22 earnings per share for the current year.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.